Assessing the Efficacy of Probiotics in Prevention of NEC in Preterm Babies
2 other identifiers
interventional
196
1 country
1
Brief Summary
The goal of the study is to check efficacy of probiotics in preventing necrotizing enterocolitis. The main questions would be if the preterm baby developed NEC or not.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 14, 2025
CompletedFirst Posted
Study publicly available on registry
November 18, 2025
CompletedStudy Start
First participant enrolled
April 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2026
CompletedAugust 18, 2026
August 1, 2026
6 months
November 14, 2025
August 14, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Number of participants who develop NEC on probiotic vs placebo
30 days
Study Arms (2)
Probiotic group - Intervention
ACTIVE COMPARATORThis group will receive intervention
Placebo
PLACEBO COMPARATORThis group will receive 10% DW
Interventions
All preterm babies \<34 weeks Gestational age admitted within 24 hrs of life will be eligible for the study. Those full filling inclusion criteria and consenting to participate will be recruited. Consent will be obtained by team not caring for the patient. Each recruited patient will be assigned a case ID number. Based on the Randomization babies will be assigned to either the intervention group or control group. Study group: Multistrain probiotic containing a mix of Lactobacillus and Bifidobacterium spp. * Dose is 1 million international units (0.2ml or 5 drops) OD * Started as soon as feed is in initiated
Eligibility Criteria
You may qualify if:
- Male and female preterm infants with a gestational age less than 35 weeks.
- All indoor patients and outdoor patients who present within 24hrs of birth
You may not qualify if:
- Infants with congenital or developmental gastrointestinal disorders for example omphalocele, malrotation, gastroschisis.
- Infants with severe sepsis or gastrointestinal bleeding on presentation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hayatabad Medical Complex
Peshawar, KPK, 25000, Pakistan
Related Publications (1)
Pammi M, Cope J, Tarr PI, Warner BB, Morrow AL, Mai V, Gregory KE, Kroll JS, McMurtry V, Ferris MJ, Engstrand L, Lilja HE, Hollister EB, Versalovic J, Neu J. Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome. 2017 Mar 9;5(1):31. doi: 10.1186/s40168-017-0248-8.
PMID: 28274256RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Romisa Romisa, MBBS, FCPS
Hyatabad Medical Complex
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 14, 2025
First Posted
November 18, 2025
Study Start
April 1, 2026
Primary Completion
September 30, 2026
Study Completion
September 30, 2026
Last Updated
August 18, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share